First-in-man trial using the PCI technology published in Lancet Oncology
Kristian Berg, the founder of the intracellular drug delivery technology photochemical internalisation (PCI) recently co-authored a paper that were published in Lancet Oncology (journal impact factor 24.69) together with collaborators at the University College London (UCL) Hospitals, London where the study was conducted and PCI Biotech.
The article "Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial" was also commented in the same issue of Lancet Oncology.
This study, which was conducted at the UCL, shows promising results of using TPCS2a-mediated photochemical internalisation as a drug delivery technology to enhance the efficacy of the chemotherapeutic agent bleomycin in heavily pre-treated cancer patient population and suggest that this treatment could have an important role in interventional oncology. It also paves the way for further clinical development of the PCI method and for testing of the technology with other drug molecules on different tumour types.
Link to paper:
Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial.
Sultan AA, Jerjes W, Berg K, Høgset A, Mosse CA, Hamoudi R, Hamdoon Z, Simeon C, Carnell D, Forster M, Hopper C.
Lancet Oncol. 2016 Sep;17(9):1217-29. doi: 10.1016/S1470-2045(16)30224-8.
In the same issue the paper was commented.
Link to comment:
Photochemical internalisation for solid malignancies.
Lancet Oncol. 2016 Sep;17(9):1173-4. doi: 10.1016/S1470-2045(16)30274-1.